Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
FOLD Transcript
Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights strong financial performance, with significant revenue growth and a shift to GAAP profitability. Despite increased COGS, net income improved, and cash reserves grew. The Q&A section revealed positive reception of product labels and strategic market expansion plans. However, vague responses on revenue acceleration and supply stability pose some concerns. Overall, the positive financial results, optimistic guidance, and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call reveals mixed signals. Financial performance shows increased expenses and net loss, though non-GAAP income remains positive. Product development and market expansion are promising, with strong market share gains and regulatory progress. However, the decreased revenue growth guidance and increased COGS raise concerns. The Q&A highlights confidence in IP and manufacturing progress but lacks specifics on timelines and COGS impact. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
FOLD Slides
FOLD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
